$BioNTech (BNTX.US)$🎯 2024.4.8 The current price is 89.56, ...

New data: 23Q3 and 23Q4. Revenue, operating profit, and net profit all continued to shrink, but there was a sharp improvement for two consecutive quarters compared to the previous month.

In 2023, revenue shrank 78%, operating profit shrank 92.7%, and net profit shrank 90.1%.

The balance ratio fell from 13.9% to 12%, total assets declined slightly, and net assets increased slightly. Cash on the asset side has increased, accounts receivable have declined sharply, and interest-bearing liabilities on the debt side can still rarely be ignored.

The net operating cash flow was lower than the net investment, and there was no shareholder surplus, but it was generated quite a bit over 5 years.

Currently, the price-earnings ratio is 21.4. If you follow the current improvement trend, net profit should reach about 2 billion dollars in 2024, the price-earnings ratio will drop to about 10, and the valuation is still not high, so you can choose carefully (⭐️)